{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:42:53Z","timestamp":1792788173825,"version":"4.5.0"},"reference-count":146,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271978"],"award-info":[{"award-number":["82271978"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research Project of Jiangsu Society of Traditional Chinese Medicine","award":["CYTF2024045"],"award-info":[{"award-number":["CYTF2024045"]}]},{"name":"Research Project of Jiangsu Society of Traditional Chinese Medicine","award":["ZXFZ2026084"],"award-info":[{"award-number":["ZXFZ2026084"]}]},{"name":"Youth Science Fund Project of Kunshan Hospital of Chinese Medicine","award":["2024QNJJ02"],"award-info":[{"award-number":["2024QNJJ02"]}]},{"name":"Kunshan Youth Science and Technology Talent Support Project","award":["2025KSTJ04"],"award-info":[{"award-number":["2025KSTJ04"]}]},{"name":"Research Project of the Jiangsu Provincial Health Commission","award":["Z2025005"],"award-info":[{"award-number":["Z2025005"]}],"id":[{"id":"https:\/\/ror.org\/03eqskn19","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Insights Imaging"],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality worldwide. In at-risk populations, noninvasive imaging diagnosis relies primarily on the vascular hallmarks of arterial phase hyperenhancement and washout appearance. However, these features are often absent in early hepatocarcinogenesis, thereby limiting timely detection. Gadoxetic acid-enhanced MRI has expanded the role of imaging in HCC, yet its clinical value is often oversimplified as a comparison of diagnostic performance with CT or extracellular contrast MRI. A critical issue is that the same imaging feature, particularly hepatobiliary phase (HBP) hypointensity, carries different diagnostic consequences across international frameworks. Because HBP signal loss reflects early hepatocellular dysfunction that may precede typical vascular hallmarks, gadoxetic acid-enhanced MRI provides a biologically driven sensitivity advantage for detecting small and early-stage HCC. However, its apparent performance varies largely according to diagnostic intent: sensitivity-oriented Asian guidelines incorporate HBP hypointensity as a major feature to enable earlier detection, whereas Western guidelines prioritize specificity in high-stakes decision contexts, such as liver transplantation, and therefore restrict its diagnostic weight. This intent-dependent interpretation explains much of the inconsistency reported in the literature and underscores the limitations of pooled, guideline-agnostic performance estimates. Beyond diagnosis, HBP imaging also offers complementary information for assessing treatment response, although it remains underutilized in current criteria. Overall, the clinical value of gadoxetic acid-enhanced MRI lies not in universal superiority but in context-aligned application, shifting the focus from modality comparison to optimization according to downstream clinical consequences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            <jats:bold>Question<\/jats:bold>\n                            Gadoxetic acid-enhanced MRI is interpreted differently across international hepatocellular carcinoma diagnostic guidelines, resulting in uncertainty regarding optimal imaging criteria and clinical decision-making.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            <jats:bold>Findings<\/jats:bold>\n                            Hepatobiliary phase hypointensity reflects early hepatocellular dysfunction and improves sensitivity for small and early-stage HCC, but its impact varies according to diagnostic intent.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            <jats:bold>Critical Relevance Statement<\/jats:bold>\n                            An intent-aligned interpretation strategy may help reconcile guideline heterogeneity and optimize the use of gadoxetic acid-enhanced MRI, particularly in the evaluation of small HCC.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13244-026-02402-5","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T04:25:15Z","timestamp":1790569515000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hepatobiliary phase imaging in HCC: revisiting diagnostic algorithms and clinical utility of gadoxetic acid-enhanced MRI across international guidelines"],"prefix":"10.1186","volume":"17","author":[{"given":"Shuwei","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghong","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9356-4393","authenticated-orcid":false,"given":"Tian","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6253-8311","authenticated-orcid":false,"given":"Yuan-Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"2402_CR1","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41571-024-00868-0","volume":"21","author":"JM Llovet","year":"2024","unstructured":"Llovet JM, Pinyol R, Yarchoan M et al (2024) Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nat Rev Clin Oncol 21:294\u2013311. https:\/\/doi.org\/10.1038\/s41571-024-00868-0","journal-title":"Nat Rev Clin Oncol"},{"key":"2402_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.jhep.2019.12.011","volume":"72","author":"A Paisant","year":"2020","unstructured":"Paisant A, Vilgrain V, Riou J et al (2020) Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs. J Hepatol 72:937\u2013945. https:\/\/doi.org\/10.1016\/j.jhep.2019.12.011","journal-title":"J Hepatol"},{"key":"2402_CR3","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1007\/s00330-011-2165-8","volume":"21","author":"A Kitao","year":"2011","unstructured":"Kitao A, Matsui O, Yoneda N et al (2011) The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol 21:2056\u20132066. https:\/\/doi.org\/10.1007\/s00330-011-2165-8","journal-title":"Eur Radiol"},{"key":"2402_CR4","doi-asserted-by":"publisher","unstructured":"Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) 2022 KLCA\u2013NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol 28:583\u2013705. https:\/\/doi.org\/10.3350\/cmh.2022.0294","DOI":"10.3350\/cmh.2022.0294"},{"key":"2402_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000514174","volume":"10","author":"M Kudo","year":"2021","unstructured":"Kudo M, Kawamura Y, Hasegawa K et al (2021) Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer 10:181\u2013223. https:\/\/doi.org\/10.1159\/000514174","journal-title":"Liver Cancer"},{"key":"2402_CR6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","volume":"11","author":"M Omata","year":"2017","unstructured":"Omata M, Cheng AL, Kokudo N et al (2017) Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 11:317\u2013370. https:\/\/doi.org\/10.1007\/s12072-017-9799-9","journal-title":"Hepatol Int"},{"key":"2402_CR7","unstructured":"American College of Radiology (2026) CT\/MRI LI-RADS v2018 https:\/\/edge.sitecorecloud.io\/americancoldf5f-acrorgf92a-productioncb02-3650\/media\/ACR\/Files\/RADS\/LI-RADS\/LI-RADS-CT-MRI-2018-Core.pdf. Accessed 9 Jan 2026"},{"key":"2402_CR8","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver (2024) EASL clinical practice guidelines on the management of hepatocellular carcinoma. J Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2024.08.028","DOI":"10.1016\/j.jhep.2024.08.028"},{"key":"2402_CR9","unstructured":"OPTN (2025) Organ procurement and transplantation network website OPTN policies 2025. https:\/\/optn.transplant.hrsa.gov\/media\/eavh5bf3\/optn_policies.pdf. Accessed 8 Jan 2025"},{"key":"2402_CR10","doi-asserted-by":"publisher","first-page":"e070364","DOI":"10.1136\/bmjopen-2022-070364","volume":"14","author":"C Zhang","year":"2024","unstructured":"Zhang C, Chen X, Wang J, Luo T (2024) Diagnostic values of contrast-enhanced MRI and contrast-enhanced CT for evaluating the response of hepatocellular carcinoma after transarterial chemoembolisation: a meta-analysis. BMJ Open 14:e070364. https:\/\/doi.org\/10.1136\/bmjopen-2022-070364","journal-title":"BMJ Open"},{"key":"2402_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-023-00532-3","volume":"23","author":"KS Jhaveri","year":"2023","unstructured":"Jhaveri KS, Babaei Jandaghi A, Bhayana R et al (2023) Prospective evaluation of Gadoxetate-enhanced magnetic resonance imaging and computed tomography for hepatocellular carcinoma detection and transplant eligibility assessment with explant histopathology correlation. Cancer Imaging 23:22. https:\/\/doi.org\/10.1186\/s40644-023-00532-3","journal-title":"Cancer Imaging"},{"key":"2402_CR12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1148\/radiol.14132362","volume":"273","author":"JY Choi","year":"2014","unstructured":"Choi JY, Lee JM, Sirlin CB (2014) CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 273:30\u201350. https:\/\/doi.org\/10.1148\/radiol.14132362","journal-title":"Radiology"},{"key":"2402_CR13","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1007\/s00330-010-1812-9","volume":"20","author":"S Kogita","year":"2010","unstructured":"Kogita S, Imai Y, Okada M et al (2010) Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol 20:2405\u20132413. https:\/\/doi.org\/10.1007\/s00330-010-1812-9","journal-title":"Eur Radiol"},{"key":"2402_CR14","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/jmri.26540","volume":"49","author":"V Chernyak","year":"2019","unstructured":"Chernyak V, Fowler KJ, Heiken JP, Sirlin CB (2019) Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS). J Magn Reson Imaging 49:1236\u20131252. https:\/\/doi.org\/10.1002\/jmri.26540","journal-title":"J Magn Reson Imaging"},{"key":"2402_CR15","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/641685","volume":"2014","author":"M Matsuda","year":"2014","unstructured":"Matsuda M, Ichikawa T, Amemiya H et al (2014) Preoperative gadoxetic Acid-enhanced MRI and simultaneous treatment of early hepatocellular carcinoma prolonged recurrence-free survival of progressed hepatocellular carcinoma patients after hepatic resection. HPB Surg 2014:641685. https:\/\/doi.org\/10.1155\/2014\/641685","journal-title":"HPB Surg"},{"key":"2402_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1148\/radiol.2020192275","volume":"296","author":"I Joo","year":"2020","unstructured":"Joo I, Kim SY, Kang TW et al (2020) Radiologic-pathologic correlation of hepatobiliary phase hypointense nodules without arterial phase hyperenhancement at gadoxetic acid-enhanced MRI: a multicenter study. Radiology 296:335\u2013345. https:\/\/doi.org\/10.1148\/radiol.2020192275","journal-title":"Radiology"},{"key":"2402_CR17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11547-018-0873-8","volume":"123","author":"M Galia","year":"2018","unstructured":"Galia M, Agnello F, Sparacia G et al (2018) Evolution of indeterminate hepatocellular nodules at Gd-EOB-DPTA-enhanced MRI in cirrhotic patients. Radiol Med 123:489\u2013497. https:\/\/doi.org\/10.1007\/s11547-018-0873-8","journal-title":"Radiol Med"},{"key":"2402_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2020.109018","volume":"128","author":"F Vernuccio","year":"2020","unstructured":"Vernuccio F, Cannella R, Choudhury KR, Meyer M, Furlan A, Marin D (2020) Hepatobiliary phase hypointensity predicts progression to hepatocellular carcinoma for intermediate-high risk observations, but not time to progression. Eur J Radiol 128:109018. https:\/\/doi.org\/10.1016\/j.ejrad.2020.109018","journal-title":"Eur J Radiol"},{"key":"2402_CR19","doi-asserted-by":"publisher","first-page":"W57","DOI":"10.2214\/ajr.18.20979","volume":"213","author":"F Vernuccio","year":"2019","unstructured":"Vernuccio F, Cannella R, Meyer M et al (2019) LI-RADS: diagnostic performance of hepatobiliary phase hypointensity and major imaging features of LR-3 and LR-4 lesions measuring 10\u201319 mm with arterial phase hyperenhancement. AJR Am J Roentgenol 213:W57\u2013W65. https:\/\/doi.org\/10.2214\/ajr.18.20979","journal-title":"AJR Am J Roentgenol"},{"key":"2402_CR20","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1007\/s00330-019-06645-3","volume":"30","author":"JH Kang","year":"2020","unstructured":"Kang JH, Choi SH, Byun JH et al (2020) Ancillary features in the Liver Imaging Reporting and Data System: how to improve diagnosis of hepatocellular carcinoma \u2264\u20093 cm on magnetic resonance imaging. Eur Radiol 30:2881\u20132889. https:\/\/doi.org\/10.1007\/s00330-019-06645-3","journal-title":"Eur Radiol"},{"key":"2402_CR21","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1007\/s00330-022-09282-5","volume":"33","author":"P Huang","year":"2023","unstructured":"Huang P, Zhou C, Wu F et al (2023) An improved diagnostic algorithm for subcentimeter hepatocellular carcinoma on gadoxetic acid-enhanced MRI. Eur Radiol 33:2735\u20132745. https:\/\/doi.org\/10.1007\/s00330-022-09282-5","journal-title":"Eur Radiol"},{"key":"2402_CR22","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1007\/s00330-020-06698-9","volume":"30","author":"R Cannella","year":"2020","unstructured":"Cannella R, Vernuccio F, Sagreiya H et al (2020) Liver imaging reporting and data system (LI-RADS) v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations \u2265\u200910 mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinoma. Eur Radiol 30:3770\u20133781. https:\/\/doi.org\/10.1007\/s00330-020-06698-9","journal-title":"Eur Radiol"},{"key":"2402_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.21037\/atm.2020.02.38","volume":"9","author":"Y Li","year":"2021","unstructured":"Li Y, Chen J, Weng S et al (2021) Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma. Ann Transl Med 9:55. https:\/\/doi.org\/10.21037\/atm.2020.02.38","journal-title":"Ann Transl Med"},{"key":"2402_CR24","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1007\/s00330-018-5727-1","volume":"29","author":"I Joo","year":"2019","unstructured":"Joo I, Lee JM, Lee DH, Jeon JH, Han JK (2019) Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: Can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features? Eur Radiol 29:1724\u20131732. https:\/\/doi.org\/10.1007\/s00330-018-5727-1","journal-title":"Eur Radiol"},{"key":"2402_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1148\/radiol.2015150177","volume":"278","author":"AS Kierans","year":"2016","unstructured":"Kierans AS, Kang SK, Rosenkrantz AB (2016) The diagnostic performance of dynamic contrast-enhanced MR imaging for detection of small hepatocellular carcinoma measuring up to 2 cm: a meta-analysis. Radiology 278:82\u201394. https:\/\/doi.org\/10.1148\/radiol.2015150177","journal-title":"Radiology"},{"key":"2402_CR26","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.jhep.2016.01.018","volume":"64","author":"SH Choi","year":"2016","unstructured":"Choi SH, Byun JH, Lim YS et al (2016) Diagnostic criteria for hepatocellular carcinoma \u2a7d3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging. J Hepatol 64:1099\u20131107. https:\/\/doi.org\/10.1016\/j.jhep.2016.01.018","journal-title":"J Hepatol"},{"key":"2402_CR27","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1007\/s00330-015-3686-3","volume":"25","author":"I Joo","year":"2015","unstructured":"Joo I, Lee JM, Lee DH, Jeon JH, Han JK, Choi BI (2015) Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: Can hypointensity on the hepatobiliary phase be used as an alternative to washout? Eur Radiol 25:2859\u20132868. https:\/\/doi.org\/10.1007\/s00330-015-3686-3","journal-title":"Eur Radiol"},{"key":"2402_CR28","doi-asserted-by":"publisher","first-page":"8357","DOI":"10.3748\/wjg.v19.i45.8357","volume":"19","author":"S Phongkitkarun","year":"2013","unstructured":"Phongkitkarun S, Limsamutpetch K, Tannaphai P, Jatchavala J (2013) Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients. World J Gastroenterol 19:8357\u20138365. https:\/\/doi.org\/10.3748\/wjg.v19.i45.8357","journal-title":"World J Gastroenterol"},{"key":"2402_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1148\/radiol.14140141","volume":"274","author":"DH Lee","year":"2015","unstructured":"Lee DH, Lee JM, Baek JH, Shin CI, Han JK, Choi BI (2015) Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings. Radiology 274:149\u2013160. https:\/\/doi.org\/10.1148\/radiol.14140141","journal-title":"Radiology"},{"key":"2402_CR30","doi-asserted-by":"publisher","unstructured":"Yoon JH, Chang W, Kim YK et al (2025) Comparison of gadoxetic acid-enhanced liver magnetic resonance imaging and contrast-enhanced computed tomography for the noninvasive diagnosis of hepatocellular carcinoma. Liver Cancer. https:\/\/doi.org\/10.1159\/000545965","DOI":"10.1159\/000545965"},{"key":"2402_CR31","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1148\/radiol.14131996","volume":"271","author":"MH Yu","year":"2014","unstructured":"Yu MH, Kim JH, Yoon JH et al (2014) Small (\u2264 1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging. Radiology 271:748\u2013760. https:\/\/doi.org\/10.1148\/radiol.14131996","journal-title":"Radiology"},{"key":"2402_CR32","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1111\/liv.14133","volume":"39","author":"C Ayuso","year":"2019","unstructured":"Ayuso C, Forner A, Darnell A et al (2019) Prospective evaluation of gadoxetic acid magnetic resonance for the diagnosis of hepatocellular carcinoma in newly detected nodules \u2264 2 cm in cirrhosis. Liver Int 39:1281\u20131291. https:\/\/doi.org\/10.1111\/liv.14133","journal-title":"Liver Int"},{"key":"2402_CR33","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s00261-021-03339-7","volume":"47","author":"S Xie","year":"2022","unstructured":"Xie S, Zhang Y, Chen J et al (2022) Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10\u201319 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI? Abdom Radiol (NY) 47:596\u2013607. https:\/\/doi.org\/10.1007\/s00261-021-03339-7","journal-title":"Abdom Radiol (NY)"},{"key":"2402_CR34","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3348\/kjr.2020.1143","volume":"22","author":"YY Kim","year":"2021","unstructured":"Kim YY, Kim YK, Min JH et al (2021) Intraindividual comparison of hepatocellular carcinoma washout between MRIs with hepatobiliary and extracellular contrast agents. Korean J Radiol 22:725\u2013734. https:\/\/doi.org\/10.3348\/kjr.2020.1143","journal-title":"Korean J Radiol"},{"key":"2402_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2024.106784","volume":"81","author":"B Lin","year":"2025","unstructured":"Lin B, Zhang W, Jiang Y et al (2025) Diagnostic performance of LR-5 based on hypointensity on Gd-EOB-DTPA-enhanced MRI in the hepatobiliary phase for sHCC using LI-RADS v2018 criteria. Clin Radiol 81:106784. https:\/\/doi.org\/10.1016\/j.crad.2024.106784","journal-title":"Clin Radiol"},{"key":"2402_CR36","doi-asserted-by":"publisher","first-page":"7715","DOI":"10.1007\/s00330-021-07807-y","volume":"31","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Tang W, Xie S et al (2021) The role of lesion hypointensity on gadobenate dimeglumine-enhanced hepatobiliary phase MRI as an additional major imaging feature for HCC classification using LI-RADS v2018 criteria. Eur Radiol 31:7715\u20137724. https:\/\/doi.org\/10.1007\/s00330-021-07807-y","journal-title":"Eur Radiol"},{"key":"2402_CR37","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1148\/radiol.2019182587","volume":"291","author":"DH Kim","year":"2019","unstructured":"Kim DH, Choi SH, Kim SY, Kim MJ, Lee SS, Byun JH (2019) Gadoxetic acid-enhanced MRI of hepatocellular carcinoma: value of washout in transitional and hepatobiliary phases. Radiology 291:651\u2013657. https:\/\/doi.org\/10.1148\/radiol.2019182587","journal-title":"Radiology"},{"key":"2402_CR38","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3350\/cmh.2021.0361","volume":"28","author":"J Park","year":"2022","unstructured":"Park J, Lee JM, Kim TH, Yoon JH (2022) Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound. Clin Mol Hepatol 28:362\u2013379. https:\/\/doi.org\/10.3350\/cmh.2021.0361","journal-title":"Clin Mol Hepatol"},{"key":"2402_CR39","doi-asserted-by":"publisher","DOI":"10.1148\/rg.240090","volume":"45","author":"KC Harper","year":"2025","unstructured":"Harper KC, Ronot M, Wells ML et al (2025) Hypointense findings on hepatobiliary phase MR images. Radiographics 45:e240090. https:\/\/doi.org\/10.1148\/rg.240090","journal-title":"Radiographics"},{"key":"2402_CR40","doi-asserted-by":"publisher","first-page":"5134","DOI":"10.1007\/s00330-022-08665-y","volume":"32","author":"J Pan","year":"2022","unstructured":"Pan J, Tao Y, Chi X, Yang L, Zhao Y, Chen F (2022) Do transition and hepatobiliary phase hypointensity improve LI-RADS categorization as an alternative washout: a systematic review and meta-analysis. Eur Radiol 32:5134\u20135143. https:\/\/doi.org\/10.1007\/s00330-022-08665-y","journal-title":"Eur Radiol"},{"key":"2402_CR41","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.cgh.2019.12.010","volume":"18","author":"JH Min","year":"2020","unstructured":"Min JH, Kim JM, Kim YK et al (2020) Magnetic resonance imaging with extracellular contrast detects hepatocellular carcinoma with greater accuracy than with gadoxetic acid or computed tomography. Clin Gastroenterol Hepatol 18:2091\u20132100.e7. https:\/\/doi.org\/10.1016\/j.cgh.2019.12.010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2402_CR42","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1097\/rli.0000000000000562","volume":"54","author":"J Son","year":"2019","unstructured":"Son J, Hwang SH, Park S et al (2019) Imaging features of hepatocellular carcinoma: quantitative and qualitative comparison between MRI-enhanced with Gd-EOB-DTPA and Gd-DTPA. Invest Radiol 54:494\u2013499. https:\/\/doi.org\/10.1097\/rli.0000000000000562","journal-title":"Invest Radiol"},{"key":"2402_CR43","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1111\/liv.15012","volume":"41","author":"JH Min","year":"2021","unstructured":"Min JH, Kim JM, Kim YK et al (2021) EASL versus LI-RADS: Intra-individual comparison of MRI with extracellular contrast and gadoxetic acid for diagnosis of small HCC. Liver Int 41:2986\u20132996. https:\/\/doi.org\/10.1111\/liv.15012","journal-title":"Liver Int"},{"key":"2402_CR44","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/rli.0000000000000806","volume":"57","author":"DW Kim","year":"2022","unstructured":"Kim DW, Choi SH, Park T, Kim SY, Lee SS, Byun JH (2022) Transient severe motion artifact on arterial phase in gadoxetic acid-enhanced liver magnetic resonance imaging: a systematic review and meta-analysis. Invest Radiol 57:62\u201370. https:\/\/doi.org\/10.1097\/rli.0000000000000806","journal-title":"Invest Radiol"},{"key":"2402_CR45","doi-asserted-by":"publisher","first-page":"8629","DOI":"10.1007\/s00330-022-08885-2","volume":"32","author":"EB Jang","year":"2022","unstructured":"Jang EB, Kim DW, Choi SH et al (2022) Transient severe motion artifacts on gadoxetic acid-enhanced MRI: risk factor analysis in 2230 patients. Eur Radiol 32:8629\u20138638. https:\/\/doi.org\/10.1007\/s00330-022-08885-2","journal-title":"Eur Radiol"},{"key":"2402_CR46","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/rli.0000000000000990","volume":"59","author":"S Ichikawa","year":"2024","unstructured":"Ichikawa S, Goshima S (2024) Gadoxetic acid-enhanced liver MRI: everything you need to know. Invest Radiol 59:53\u201368. https:\/\/doi.org\/10.1097\/rli.0000000000000990","journal-title":"Invest Radiol"},{"key":"2402_CR47","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182\u2013236. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019","DOI":"10.1016\/j.jhep.2018.03.019"},{"key":"2402_CR48","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1148\/radiol.2021204529","volume":"300","author":"A Paisant","year":"2021","unstructured":"Paisant A, Gillard M, Oberti F, Roux M, Aub\u00e9 C (2021) Validation of a diagnostic algorithm for hepatocellular carcinoma at gadoxetic acid-enhanced MRI. Radiology 300:184\u2013186. https:\/\/doi.org\/10.1148\/radiol.2021204529","journal-title":"Radiology"},{"key":"2402_CR49","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1136\/gutjnl-2017-315384","volume":"67","author":"M Renzulli","year":"2018","unstructured":"Renzulli M, Biselli M, Brocchi S et al (2018) New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. Gut 67:1674\u20131682. https:\/\/doi.org\/10.1136\/gutjnl-2017-315384","journal-title":"Gut"},{"key":"2402_CR50","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1148\/rg.2020190037","volume":"40","author":"N Fujita","year":"2020","unstructured":"Fujita N, Nishie A, Asayama Y et al (2020) Hyperintense liver masses at hepatobiliary phase gadoxetic acid-enhanced MRI: imaging appearances and clinical importance. Radiographics 40:72\u201394. https:\/\/doi.org\/10.1148\/rg.2020190037","journal-title":"Radiographics"},{"key":"2402_CR51","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.4251\/wjgo.v16.i6.2439","volume":"16","author":"R Lyu","year":"2024","unstructured":"Lyu R, Hu WJ, Wang D, Wang J, Ye YB, Jia KF (2024) Simplified liver imaging reporting and data system for the diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced magnetic resonance imaging. World J Gastrointest Oncol 16:2439\u20132448. https:\/\/doi.org\/10.4251\/wjgo.v16.i6.2439","journal-title":"World J Gastrointest Oncol"},{"key":"2402_CR52","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222801","volume":"307","author":"V Chernyak","year":"2023","unstructured":"Chernyak V, Fowler KJ, Do RKG et al (2023) LI-RADS: looking back, looking forward. Radiology 307:e222801. https:\/\/doi.org\/10.1148\/radiol.222801","journal-title":"Radiology"},{"key":"2402_CR53","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1007\/s00261-024-04730-w","volume":"50","author":"AS Kierans","year":"2025","unstructured":"Kierans AS, Fowler KJ, Chernyak V (2025) LI-RADS in 2024: recent updates, planned refinements, and future directions. Abdom Radiol (NY) 50:2868\u20132880. https:\/\/doi.org\/10.1007\/s00261-024-04730-w","journal-title":"Abdom Radiol (NY)"},{"key":"2402_CR54","doi-asserted-by":"publisher","unstructured":"Singal AG, Ghaziani TT, Mehta N et al (2023) Recall patterns and risk of primary liver cancer for subcentimeter ultrasound liver observations: a multicenter study. Hepatol Commun. https:\/\/doi.org\/10.1097\/hc9.0000000000000073","DOI":"10.1097\/hc9.0000000000000073"},{"key":"2402_CR55","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/hep.29487","volume":"67","author":"LR Roberts","year":"2018","unstructured":"Roberts LR, Sirlin CB, Zaiem F et al (2018) Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology 67:401\u2013421. https:\/\/doi.org\/10.1002\/hep.29487","journal-title":"Hepatology"},{"key":"2402_CR56","doi-asserted-by":"publisher","first-page":"901.e1","DOI":"10.1016\/j.crad.2017.05.019","volume":"72","author":"M Abd Alkhalik Basha","year":"2017","unstructured":"Abd Alkhalik Basha M, Abd El Aziz El Sammak D, El Sammak AA (2017) Diagnostic efficacy of the liver imaging-reporting and data system (LI-RADS) with CT imaging in categorising small nodules (10-20 mm) detected in the cirrhotic liver at screening ultrasound. Clin Radiol 72:901.e1\u2013901.e11. https:\/\/doi.org\/10.1016\/j.crad.2017.05.019","journal-title":"Clin Radiol"},{"key":"2402_CR57","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1148\/radiol.14140690","volume":"275","author":"YJ Lee","year":"2015","unstructured":"Lee YJ, Lee JM, Lee JS et al (2015) Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology 275:97\u2013109. https:\/\/doi.org\/10.1148\/radiol.14140690","journal-title":"Radiology"},{"key":"2402_CR58","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1007\/s00330-017-5088-1","volume":"28","author":"CJ Park","year":"2018","unstructured":"Park CJ, An C, Park S, Choi JY, Kim MJ (2018) Management of subcentimetre arterially enhancing and hepatobiliary hypointense lesions on gadoxetic acid-enhanced MRI in patients at risk for HCC. Eur Radiol 28:1476\u20131484. https:\/\/doi.org\/10.1007\/s00330-017-5088-1","journal-title":"Eur Radiol"},{"key":"2402_CR59","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1097\/TP.0b013e318208134e","volume":"91","author":"K Sugimachi","year":"2011","unstructured":"Sugimachi K, Shirabe K, Taketomi A et al (2011) Prognostic significance of preoperative imaging in recipients of living donor liver transplantation for hepatocellular carcinoma. Transplantation 91:570\u2013574. https:\/\/doi.org\/10.1097\/TP.0b013e318208134e","journal-title":"Transplantation"},{"key":"2402_CR60","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1007\/s00261-016-0807-7","volume":"41","author":"J Guo","year":"2016","unstructured":"Guo J, Seo Y, Ren S et al (2016) Diagnostic performance of contrast-enhanced multidetector computed tomography and gadoxetic acid disodium-enhanced magnetic resonance imaging in detecting hepatocellular carcinoma: direct comparison and a meta-analysis. Abdom Radiol (NY) 41:1960\u20131972. https:\/\/doi.org\/10.1007\/s00261-016-0807-7","journal-title":"Abdom Radiol (NY)"},{"key":"2402_CR61","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.12659\/msm.916451","volume":"25","author":"X Sun","year":"2019","unstructured":"Sun X, Zhang Y, Lyu N, Li X, Chen M, Zhao M (2019) The optimal management for sub-centimeter hepatocellular carcinoma: Curative treatments or follow-up? Med Sci Monit 25:4941\u20134951. https:\/\/doi.org\/10.12659\/msm.916451","journal-title":"Med Sci Monit"},{"key":"2402_CR62","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.cld.2011.03.004","volume":"15","author":"T Roskams","year":"2011","unstructured":"Roskams T (2011) Anatomic pathology of hepatocellular carcinoma: impact on prognosis and response to therapy. Clin Liver Dis 15:245\u2013259. https:\/\/doi.org\/10.1016\/j.cld.2011.03.004","journal-title":"Clin Liver Dis"},{"key":"2402_CR63","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1159\/000507923","volume":"102","author":"Y Dong","year":"2021","unstructured":"Dong Y, Teufel A, Wang WP, Dietrich CF (2021) Current opinion about hepatocellular carcinoma < 10 mm. Digestion 102:335\u2013341. https:\/\/doi.org\/10.1159\/000507923","journal-title":"Digestion"},{"key":"2402_CR64","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00535-015-1097-5","volume":"51","author":"M Tsurusaki","year":"2016","unstructured":"Tsurusaki M, Sofue K, Isoda H, Okada M, Kitajima K, Murakami T (2016) Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study. J Gastroenterol 51:71\u201379. https:\/\/doi.org\/10.1007\/s00535-015-1097-5","journal-title":"J Gastroenterol"},{"key":"2402_CR65","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00330-007-0716-9","volume":"18","author":"R Hammerstingl","year":"2008","unstructured":"Hammerstingl R, Huppertz A, Breuer J et al (2008) Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 18:457\u2013467. https:\/\/doi.org\/10.1007\/s00330-007-0716-9","journal-title":"Eur Radiol"},{"key":"2402_CR66","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.2214\/ajr.08.1262","volume":"192","author":"SH Kim","year":"2009","unstructured":"Kim SH, Kim SH, Lee J et al (2009) Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 192:1675\u20131681. https:\/\/doi.org\/10.2214\/ajr.08.1262","journal-title":"AJR Am J Roentgenol"},{"key":"2402_CR67","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1177\/0284185114534652","volume":"56","author":"KM Jang","year":"2015","unstructured":"Jang KM, Kim SH, Kim YK, Choi D (2015) Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease. Acta Radiol 56:526\u2013535. https:\/\/doi.org\/10.1177\/0284185114534652","journal-title":"Acta Radiol"},{"key":"2402_CR68","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1148\/radiol.12112517","volume":"264","author":"MJ Park","year":"2012","unstructured":"Park MJ, Kim YK, Lee MW et al (2012) Small hepatocellular carcinomas: improved sensitivity by combining gadoxetic acid-enhanced and diffusion-weighted MR imaging patterns. Radiology 264:761\u2013770. https:\/\/doi.org\/10.1148\/radiol.12112517","journal-title":"Radiology"},{"key":"2402_CR69","doi-asserted-by":"publisher","first-page":"W758","DOI":"10.2214\/ajr.10.4394","volume":"196","author":"JE Kim","year":"2011","unstructured":"Kim JE, Kim SH, Lee SJ, Rhim H (2011) Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging. AJR Am J Roentgenol 196:W758\u2013W765. https:\/\/doi.org\/10.2214\/ajr.10.4394","journal-title":"AJR Am J Roentgenol"},{"key":"2402_CR70","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v31.i2.98031","volume":"31","author":"A Urase","year":"2025","unstructured":"Urase A, Tsurusaki M, Kozuki R, Kono A, Sofue K, Ishii K (2025) Imaging characteristics of hypervascular focal nodular hyperplasia-like lesions in patients with chronic alcoholic liver disease. World J Gastroenterol 31:98031. https:\/\/doi.org\/10.3748\/wjg.v31.i2.98031","journal-title":"World J Gastroenterol"},{"key":"2402_CR71","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s00261-023-03871-8","volume":"48","author":"R Lyu","year":"2023","unstructured":"Lyu R, Hu W, Wang D, Wang J, Gao Z, Jia K (2023) LI-RADS v2018: utilizing ancillary features on gadoxetic acid-enhanced MRI to improve the diagnostic performance of small hapatocellular carcinoma (\u2264\u200920 mm). Abdom Radiol (NY) 48:1987\u20131994. https:\/\/doi.org\/10.1007\/s00261-023-03871-8","journal-title":"Abdom Radiol (NY)"},{"key":"2402_CR72","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1186\/s12876-025-04071-y","volume":"25","author":"L Yang","year":"2025","unstructured":"Yang L, Rao S, Jin K, Wu L, Zeng M, Ding Y (2025) Diagnostic performances of adding transition and hepatobiliary phase to washout in gadoxetic acid-enhanced MRI for subcentimeter hepatocellular carcinoma. BMC Gastroenterol 25:483. https:\/\/doi.org\/10.1186\/s12876-025-04071-y","journal-title":"BMC Gastroenterol"},{"key":"2402_CR73","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00330-020-07146-4","volume":"31","author":"S Lee","year":"2021","unstructured":"Lee S, Kim SS, Bae H, Shin J, Yoon JK, Kim MJ (2021) Application of liver imaging reporting and data system version 2018 ancillary features to upgrade from LR-4 to LR-5 on gadoxetic acid-enhanced MRI. Eur Radiol 31:855\u2013863. https:\/\/doi.org\/10.1007\/s00330-020-07146-4","journal-title":"Eur Radiol"},{"key":"2402_CR74","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s00330-021-08116-0","volume":"32","author":"SK Jeon","year":"2022","unstructured":"Jeon SK, Joo I, Bae JS, Park SJ, Lee JM (2022) LI-RADS v2018: how to appropriately use ancillary features in category adjustment from intermediate probability of malignancy (LR-3) to probably HCC (LR-4) on gadoxetic acid-enhanced MRI. Eur Radiol 32:46\u201355. https:\/\/doi.org\/10.1007\/s00330-021-08116-0","journal-title":"Eur Radiol"},{"key":"2402_CR75","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1007\/s00330-015-3680-9","volume":"25","author":"KD Song","year":"2015","unstructured":"Song KD, Kim SH, Lim HK, Jung SH, Sohn I, Kim HS (2015) Subcentimeter hypervascular nodule with typical imaging findings of hepatocellular carcinoma in patients with history of hepatocellular carcinoma: natural course on serial gadoxetic acid-enhanced MRI and diffusion-weighted imaging. Eur Radiol 25:2789\u20132796. https:\/\/doi.org\/10.1007\/s00330-015-3680-9","journal-title":"Eur Radiol"},{"key":"2402_CR76","doi-asserted-by":"publisher","DOI":"10.1177\/17562848241293019","volume":"17","author":"Z Xiao","year":"2024","unstructured":"Xiao Z, Yang F, Liu Z, Chen X, Ma S, Li H (2024) An overview of risk assessment and monitoring of malignant transformation in cirrhotic nodules. Therap Adv Gastroenterol 17:17562848241293019. https:\/\/doi.org\/10.1177\/17562848241293019","journal-title":"Therap Adv Gastroenterol"},{"key":"2402_CR77","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2147\/jhc.S287641","volume":"7","author":"X Sun","year":"2020","unstructured":"Sun X, Hu D, Zhang Y et al (2020) Can immediately treating subcentimeter hepatocellular carcinoma improve the survival of patients? J Hepatocell Carcinoma 7:377\u2013384. https:\/\/doi.org\/10.2147\/jhc.S287641","journal-title":"J Hepatocell Carcinoma"},{"key":"2402_CR78","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2147\/jhc.S401027","volume":"10","author":"P Huang","year":"2023","unstructured":"Huang P, Ni X, Zhou C et al (2023) Subcentimeter nodules with diagnostic hallmarks of hepatocellular carcinoma: comparison of pathological features and survival outcomes with nodules measuring 1\u20132 cm. J Hepatocell Carcinoma 10:169\u2013180. https:\/\/doi.org\/10.2147\/jhc.S401027","journal-title":"J Hepatocell Carcinoma"},{"key":"2402_CR79","doi-asserted-by":"publisher","first-page":"e248755","DOI":"10.1001\/jamanetworkopen.2024.8755","volume":"7","author":"D Daher","year":"2024","unstructured":"Daher D, Seif El Dahan K, Rich NE et al (2024) Hepatocellular carcinoma screening in a contemporary cohort of at-risk patients. JAMA Netw Open 7:e248755. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.8755","journal-title":"JAMA Netw Open"},{"key":"2402_CR80","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jhep.2022.01.023","volume":"77","author":"AG Singal","year":"2022","unstructured":"Singal AG, Zhang E, Narasimman M et al (2022) HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis. J Hepatol 77:128\u2013139. https:\/\/doi.org\/10.1016\/j.jhep.2022.01.023","journal-title":"J Hepatol"},{"key":"2402_CR81","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/1106975","volume":"2023","author":"Z Chen","year":"2023","unstructured":"Chen Z, Zheng H, Zeng W, Liu M, Chen Y (2023) Prognostic analysis on different tumor sizes for 14634 hepatocellular carcinoma patients. Eur J Cancer Care 2023:1106975. https:\/\/doi.org\/10.1155\/2023\/1106975","journal-title":"Eur J Cancer Care"},{"key":"2402_CR82","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jfma.2020.11.010","volume":"120","author":"CC Wu","year":"2021","unstructured":"Wu CC, Tseng CW, Tseng KC et al (2021) Radiofrequency ablation versus surgical resection for the treatment of solitary hepatocellular carcinoma 2 cm or smaller: a cohort study in Taiwan. J Formos Med Assoc 120:1249\u20131258. https:\/\/doi.org\/10.1016\/j.jfma.2020.11.010","journal-title":"J Formos Med Assoc"},{"key":"2402_CR83","doi-asserted-by":"publisher","first-page":"100781","DOI":"10.1016\/j.jhepr.2023.100781","volume":"5","author":"X Wu","year":"2023","unstructured":"Wu X, Lokken RP, Mehta N (2023) Optimal treatment for small HCC (<\u20093 cm): Resection, liver transplantation, or locoregional therapy? JHEP Rep 5:100781. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100781","journal-title":"JHEP Rep"},{"key":"2402_CR84","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J et al (2022) BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 76:681\u2013693. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018","journal-title":"J Hepatol"},{"key":"2402_CR85","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3348\/kjr.2018.0636","volume":"20","author":"JH Kim","year":"2019","unstructured":"Kim JH, Joo I, Lee JM (2019) Atypical appearance of hepatocellular carcinoma and its mimickers: how to solve challenging cases using gadoxetic acid-enhanced liver magnetic resonance imaging. Korean J Radiol 20:1019\u20131041. https:\/\/doi.org\/10.3348\/kjr.2018.0636","journal-title":"Korean J Radiol"},{"key":"2402_CR86","doi-asserted-by":"publisher","first-page":"544","DOI":"10.2214\/ajr.16.16414","volume":"208","author":"MH Choi","year":"2017","unstructured":"Choi MH, Choi JI, Lee YJ, Park MY, Rha SE, Lall C (2017) MRI of small hepatocellular carcinoma: typical features are less frequent below a size cutoff of 1.5 cm. AJR Am J Roentgenol 208:544\u2013551. https:\/\/doi.org\/10.2214\/ajr.16.16414","journal-title":"AJR Am J Roentgenol"},{"key":"2402_CR87","doi-asserted-by":"publisher","first-page":"130","DOI":"10.2478\/raon-2021-0004","volume":"55","author":"JD Kovac","year":"2021","unstructured":"Kovac JD, Ivanovic A, Milovanovic T, Micev M, Alessandrino F, Gore RM (2021) An overview of hepatocellular carcinoma with atypical enhancement pattern: spectrum of magnetic resonance imaging findings with pathologic correlation. Radiol Oncol 55:130\u2013143. https:\/\/doi.org\/10.2478\/raon-2021-0004","journal-title":"Radiol Oncol"},{"key":"2402_CR88","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.3748\/wjg.v26.i17.2012","volume":"26","author":"JD Kovac","year":"2020","unstructured":"Kovac JD, Milovanovic T, Dugalic V, Dumic I (2020) Pearls and pitfalls in magnetic resonance imaging of hepatocellular carcinoma. World J Gastroenterol 26:2012\u20132029. https:\/\/doi.org\/10.3748\/wjg.v26.i17.2012","journal-title":"World J Gastroenterol"},{"key":"2402_CR89","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00261-015-0592-8","volume":"41","author":"RF Hanna","year":"2016","unstructured":"Hanna RF, Miloushev VZ, Tang A et al (2016) Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdom Radiol (NY) 41:71\u201390. https:\/\/doi.org\/10.1007\/s00261-015-0592-8","journal-title":"Abdom Radiol (NY)"},{"key":"2402_CR90","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1002\/lt.24867","volume":"23","author":"X Liu","year":"2017","unstructured":"Liu X, Jiang H, Chen J, Zhou Y, Huang Z, Song B (2017) Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: a meta-analysis. Liver Transpl 23:1505\u20131518. https:\/\/doi.org\/10.1002\/lt.24867","journal-title":"Liver Transpl"},{"key":"2402_CR91","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/jmri.26199","volume":"49","author":"JH Yoon","year":"2019","unstructured":"Yoon JH, Lee JM, Lee YJ, Lee KB, Han JK (2019) Added value of sequentially performed gadoxetic acid-enhanced liver MRI for the diagnosis of small (10\u201319\u2009mm) or atypical hepatic observations at contrast-enhanced CT: a prospective comparison. J Magn Reson Imaging 49:574\u2013587. https:\/\/doi.org\/10.1002\/jmri.26199","journal-title":"J Magn Reson Imaging"},{"key":"2402_CR92","doi-asserted-by":"publisher","first-page":"939","DOI":"10.4143\/crt.2022.1645","volume":"55","author":"JK Yoon","year":"2023","unstructured":"Yoon JK, Han DH, Lee S et al (2023) Intraindividual comparison of MRIs with extracellular and hepatobiliary contrast agents for the noninvasive diagnosis of hepatocellular carcinoma using the Korean Liver Cancer Association-National Cancer Center 2022 Criteria. Cancer Res Treat 55:939\u2013947. https:\/\/doi.org\/10.4143\/crt.2022.1645","journal-title":"Cancer Res Treat"},{"key":"2402_CR93","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.233114","volume":"311","author":"JH Yoon","year":"2024","unstructured":"Yoon JH, Kim YK, Kim JW et al (2024) Comparison of four diagnostic guidelines for hepatocellular carcinoma using gadoxetic acid-enhanced liver MRI. Radiology 311:e233114. https:\/\/doi.org\/10.1148\/radiol.233114","journal-title":"Radiology"},{"key":"2402_CR94","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1007\/s00330-020-07577-z","volume":"31","author":"SH Park","year":"2021","unstructured":"Park SH, Shim YS, Kim B et al (2021) Retrospective analysis of current guidelines for hepatocellular carcinoma diagnosis on gadoxetic acid-enhanced MRI in at-risk patients. Eur Radiol 31:4751\u20134763. https:\/\/doi.org\/10.1007\/s00330-020-07577-z","journal-title":"Eur Radiol"},{"key":"2402_CR95","doi-asserted-by":"publisher","first-page":"466","DOI":"10.5009\/gnl220115","volume":"17","author":"J Shin","year":"2023","unstructured":"Shin J, Lee S, Yoon JK et al (2023) Diagnostic performance of LI-RADS v2018 versus KLCA\u2013NCC 2018 Criteria for hepatocellular carcinoma using magnetic resonance imaging with hepatobiliary agent: a systematic review and meta-analysis of comparative studies. Gut Liver 17:466\u2013474. https:\/\/doi.org\/10.5009\/gnl220115","journal-title":"Gut Liver"},{"key":"2402_CR96","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1007\/s12072-020-10040-2","volume":"14","author":"J Byun","year":"2020","unstructured":"Byun J, Choi SH, Byun JH et al (2020) Comparison of the diagnostic performance of imaging criteria for HCCs\u2009\u2264\u20093.0 cm on gadoxetate disodium-enhanced MRI. Hepatol Int 14:534\u2013543. https:\/\/doi.org\/10.1007\/s12072-020-10040-2","journal-title":"Hepatol Int"},{"key":"2402_CR97","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1007\/s00330-020-07468-3","volume":"31","author":"SH Hwang","year":"2021","unstructured":"Hwang SH, Park MS, Park S, Lim JS, Kim SU, Park YN (2021) Comparison of the current guidelines for diagnosing hepatocellular carcinoma using gadoxetic acid-enhanced magnetic resonance imaging. Eur Radiol 31:4492\u20134503. https:\/\/doi.org\/10.1007\/s00330-020-07468-3","journal-title":"Eur Radiol"},{"key":"2402_CR98","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jhep.2019.08.025","volume":"72","author":"AG Singal","year":"2020","unstructured":"Singal AG, Lampertico P, Nahon P (2020) Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol 72:250\u2013261. https:\/\/doi.org\/10.1016\/j.jhep.2019.08.025","journal-title":"J Hepatol"},{"key":"2402_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.680691","volume":"11","author":"C Zhao","year":"2021","unstructured":"Zhao C, Dai H, Shao J et al (2021) Accuracy of various forms of contrast-enhanced MRI for diagnosing hepatocellular carcinoma: a systematic review and meta-analysis. Front Oncol 11:680691. https:\/\/doi.org\/10.3389\/fonc.2021.680691","journal-title":"Front Oncol"},{"key":"2402_CR100","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.1007\/s00330-020-06881-y","volume":"30","author":"SK Jeon","year":"2020","unstructured":"Jeon SK, Lee JM, Joo I, Yoo J, Park JY (2020) Comparison of guidelines for diagnosis of hepatocellular carcinoma using gadoxetic acid-enhanced MRI in transplantation candidates. Eur Radiol 30:4762\u20134771. https:\/\/doi.org\/10.1007\/s00330-020-06881-y","journal-title":"Eur Radiol"},{"key":"2402_CR101","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-022-00497-9","volume":"22","author":"D Odedra","year":"2022","unstructured":"Odedra D, Jandaghi AB, Bhayana R et al (2022) Comparison of international guidelines for diagnosis of hepatocellular carcinoma and implications for transplant allocation in liver transplantation candidates with gadoxetic acid enhanced liver MRI versus contrast enhanced CT: a prospective study with liver explant histopathological correlation. Cancer Imaging 22:55. https:\/\/doi.org\/10.1186\/s40644-022-00497-9","journal-title":"Cancer Imaging"},{"key":"2402_CR102","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jfma.2023.11.008","volume":"123","author":"MF Chen","year":"2024","unstructured":"Chen MF, Ho MC, Kao JH et al (2024) Comparison of CT and gadoxetic acid-enhanced MRI with liver imaging reporting and data system to assess liver tumors before resection. J Formos Med Assoc 123:318\u2013324. https:\/\/doi.org\/10.1016\/j.jfma.2023.11.008","journal-title":"J Formos Med Assoc"},{"key":"2402_CR103","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s11604-019-00855-x","volume":"37","author":"S Nakao","year":"2019","unstructured":"Nakao S, Tanabe M, Okada M et al (2019) Liver imaging reporting and data system (LI-RADS) v2018: comparison between computed tomography and gadoxetic acid-enhanced magnetic resonance imaging. Jpn J Radiol 37:651\u2013659. https:\/\/doi.org\/10.1007\/s11604-019-00855-x","journal-title":"Jpn J Radiol"},{"key":"2402_CR104","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s12072-020-10100-7","volume":"14","author":"DW Kim","year":"2020","unstructured":"Kim DW, Choi SH, Kim SY et al (2020) Diagnostic performance of MRI for HCC according to contrast agent type: a systematic review and meta-analysis. Hepatol Int 14:1009\u20131022. https:\/\/doi.org\/10.1007\/s12072-020-10100-7","journal-title":"Hepatol Int"},{"key":"2402_CR105","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.220646","volume":"307","author":"S Lee","year":"2023","unstructured":"Lee S, Kim YY, Shin J et al (2023) Percentages of hepatocellular carcinoma in LI-RADS categories with CT and MRI: a systematic review and meta-analysis. Radiology 307:e220646. https:\/\/doi.org\/10.1148\/radiol.220646","journal-title":"Radiology"},{"key":"2402_CR106","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1002\/hep.30122","volume":"68","author":"JH Min","year":"2018","unstructured":"Min JH, Kim JM, Kim YK et al (2018) Prospective intraindividual comparison of magnetic resonance imaging with gadoxetic acid and extracellular contrast for diagnosis of hepatocellular carcinomas using the liver imaging reporting and data system. Hepatology 68:2254\u20132266. https:\/\/doi.org\/10.1002\/hep.30122","journal-title":"Hepatology"},{"key":"2402_CR107","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1007\/s00330-020-06753-5","volume":"30","author":"DI Cha","year":"2020","unstructured":"Cha DI, Choi GS, Kim YK et al (2020) Extracellular contrast-enhanced MRI with diffusion-weighted imaging for HCC diagnosis: prospective comparison with gadoxetic acid using LI-RADS. Eur Radiol 30:3723\u20133734. https:\/\/doi.org\/10.1007\/s00330-020-06753-5","journal-title":"Eur Radiol"},{"key":"2402_CR108","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s12072-019-10002-3","volume":"14","author":"S Lee","year":"2020","unstructured":"Lee S, Kim MJ, Kim SS et al (2020) Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging. Hepatol Int 14:70\u201379. https:\/\/doi.org\/10.1007\/s12072-019-10002-3","journal-title":"Hepatol Int"},{"key":"2402_CR109","doi-asserted-by":"publisher","first-page":"157","DOI":"10.17998\/jlc.2023.02.07","volume":"23","author":"JK Yoon","year":"2023","unstructured":"Yoon JK, Lee S, Hwang JA, Lee JE, Kim SS, Kim MJ (2023) Diagnostic performance of the 2022 KLCA\u2013NCC criteria for hepatocellular carcinoma on magnetic resonance imaging with extracellular contrast and hepatobiliary agents: comparison with the 2018 KLCA\u2013NCC criteria. J Liver Cancer 23:157\u2013165. https:\/\/doi.org\/10.17998\/jlc.2023.02.07","journal-title":"J Liver Cancer"},{"key":"2402_CR110","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"2402_CR111","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/s1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18:e143\u2013e152. https:\/\/doi.org\/10.1016\/s1470-2045(17)30074-8","journal-title":"Lancet Oncol"},{"key":"2402_CR112","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/s0168-8278(01)00130-1","volume":"35","author":"J Bruix","year":"2001","unstructured":"Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421\u2013430. https:\/\/doi.org\/10.1016\/s0168-8278(01)00130-1","journal-title":"J Hepatol"},{"key":"2402_CR113","unstructured":"American College of Radiology (2024) Liver imaging reporting and data system (LI-RADS). American College of Radiology website. https:\/\/edge.sitecorecloud.io\/americancoldf5f-acrorgf92a-productioncb02-3650\/media\/ACR\/Files\/RADS\/LI-RADS\/LI-RADS-CTMR-Radiation-TRA-v2024-Core.pdf Accessed 9 Jan 2026"},{"key":"2402_CR114","unstructured":"American College of Radiology (2024) Liver imaging reporting and data system (LI-RADS). American College of Radiology website. https:\/\/edge.sitecorecloud.io\/americancoldf5f-acrorgf92a-productioncb02-3650\/media\/ACR\/Files\/RADS\/LI-RADS\/LI-RADS-CTMR-Nonradiation-TRA-v2024-Core.pdf Accessed 9 Jan 2026"},{"key":"2402_CR115","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41392-024-01991-1","volume":"9","author":"Y Chen","year":"2024","unstructured":"Chen Y, Zhang J, Hu W et al (2024) Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study. Signal Transduct Target Ther 9:280. https:\/\/doi.org\/10.1038\/s41392-024-01991-1","journal-title":"Signal Transduct Target Ther"},{"key":"2402_CR116","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1200\/jco.22.00343","volume":"41","author":"JA Chesney","year":"2023","unstructured":"Chesney JA, Ribas A, Long GV et al (2023) Randomized, double-blind, placebo-controlled, global phase iii trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma. J Clin Oncol 41:528\u2013540. https:\/\/doi.org\/10.1200\/jco.22.00343","journal-title":"J Clin Oncol"},{"key":"2402_CR117","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jvir.2008.09.034","volume":"20","author":"SJ Hunt","year":"2009","unstructured":"Hunt SJ, Yu W, Weintraub J, Prince MR, Kothary N (2009) Radiologic monitoring of hepatocellular carcinoma tumor viability after transhepatic arterial chemoembolization: estimating the accuracy of contrast-enhanced cross-sectional imaging with histopathologic correlation. J Vasc Interv Radiol 20:30\u201338. https:\/\/doi.org\/10.1016\/j.jvir.2008.09.034","journal-title":"J Vasc Interv Radiol"},{"key":"2402_CR118","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1148\/radiol.2020192797","volume":"296","author":"S Park","year":"2020","unstructured":"Park S, Joo I, Lee DH et al (2020) Diagnostic performance of LI-RADS treatment response algorithm for hepatocellular carcinoma: adding ancillary features to MRI compared with enhancement patterns at CT and MRI. Radiology 296:554\u2013561. https:\/\/doi.org\/10.1148\/radiol.2020192797","journal-title":"Radiology"},{"key":"2402_CR119","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1007\/s00261-021-03076-x","volume":"46","author":"A Aslam","year":"2021","unstructured":"Aslam A, Kamath A, Spieler B et al (2021) Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents. Abdom Radiol (NY) 46:3565\u20133578. https:\/\/doi.org\/10.1007\/s00261-021-03076-x","journal-title":"Abdom Radiol (NY)"},{"key":"2402_CR120","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00261-023-04143-1","volume":"49","author":"S Zhou","year":"2024","unstructured":"Zhou S, Wang S, Xiang J et al (2024) Diagnostic performance of MRI for residual or recurrent hepatocellular carcinoma after locoregional treatment according to contrast agent type: a systematic review and meta\u2011analysis. Abdom Radiol (NY) 49:471\u2013483. https:\/\/doi.org\/10.1007\/s00261-023-04143-1","journal-title":"Abdom Radiol (NY)"},{"key":"2402_CR121","doi-asserted-by":"publisher","first-page":"589","DOI":"10.2214\/ajr.11.6844","volume":"198","author":"H Watanabe","year":"2012","unstructured":"Watanabe H, Kanematsu M, Goshima S et al (2012) Is gadoxetate disodium-enhanced MRI useful for detecting local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy? AJR Am J Roentgenol 198:589\u2013595. https:\/\/doi.org\/10.2214\/ajr.11.6844","journal-title":"AJR Am J Roentgenol"},{"key":"2402_CR122","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.jvir.2015.03.009","volume":"26","author":"J Schelhorn","year":"2015","unstructured":"Schelhorn J, Best J, Reinboldt MP et al (2015) Therapy response assessment after radioembolization of patients with hepatocellular carcinoma-comparison of MR imaging with gadolinium ethoxybenzyl diethylenetriamine penta-acetic acid and gadobutrol. J Vasc Interv Radiol 26:972\u2013979. https:\/\/doi.org\/10.1016\/j.jvir.2015.03.009","journal-title":"J Vasc Interv Radiol"},{"key":"2402_CR123","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1007\/s00330-019-06623-9","volume":"30","author":"SW Kim","year":"2020","unstructured":"Kim SW, Joo I, Kim HC et al (2020) LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features. Eur Radiol 30:2861\u20132870. https:\/\/doi.org\/10.1007\/s00330-019-06623-9","journal-title":"Eur Radiol"},{"key":"2402_CR124","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00261-018-1775-x","volume":"44","author":"J Rimola","year":"2019","unstructured":"Rimola J, Davenport MS, Liu PS et al (2019) Diagnostic accuracy of MRI with extracellular vs. hepatobiliary contrast material for detection of residual hepatocellular carcinoma after locoregional treatment. Abdom Radiol (NY) 44:549\u2013558. https:\/\/doi.org\/10.1007\/s00261-018-1775-x","journal-title":"Abdom Radiol (NY)"},{"key":"2402_CR125","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1007\/s00261-019-01968-7","volume":"44","author":"JH Yim","year":"2019","unstructured":"Yim JH, Kim YK, Min JH, Lee J, Kang TW, Lee SJ (2019) Diagnosis of recurrent HCC: intraindividual comparison of gadoxetic acid MRI and extracellular contrast-enhanced MRI. Abdom Radiol (NY) 44:2366\u20132376. https:\/\/doi.org\/10.1007\/s00261-019-01968-7","journal-title":"Abdom Radiol (NY)"},{"key":"2402_CR126","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s00330-019-06351-0","volume":"30","author":"J Rimola","year":"2020","unstructured":"Rimola J, Forner A, Sapena V et al (2020) Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma. Eur Radiol 30:186\u2013194. https:\/\/doi.org\/10.1007\/s00330-019-06351-0","journal-title":"Eur Radiol"},{"key":"2402_CR127","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.3348\/kjr.2020.1394","volume":"22","author":"SY Youn","year":"2021","unstructured":"Youn SY, Kim DH, Choi JI et al (2021) Usefulness of arterial subtraction in applying liver imaging reporting and data system (LI-RADS) treatment response algorithm to gadoxetic acid-enhanced MRI. Korean J Radiol 22:1289\u20131299. https:\/\/doi.org\/10.3348\/kjr.2020.1394","journal-title":"Korean J Radiol"},{"key":"2402_CR128","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/jmri.21689","volume":"29","author":"T Tamada","year":"2009","unstructured":"Tamada T, Ito K, Sone T et al (2009) Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA. J Magn Reson Imaging 29:636\u2013640. https:\/\/doi.org\/10.1002\/jmri.21689","journal-title":"J Magn Reson Imaging"},{"key":"2402_CR129","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1148\/radiol.2015150642","volume":"279","author":"U Motosugi","year":"2016","unstructured":"Motosugi U, Bannas P, Bookwalter CA, Sano K, Reeder SB (2016) An investigation of transient severe motion related to gadoxetic acid-enhanced MR imaging. Radiology 279:93\u2013102. https:\/\/doi.org\/10.1148\/radiol.2015150642","journal-title":"Radiology"},{"key":"2402_CR130","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1148\/radiol.10091885","volume":"256","author":"U Motosugi","year":"2010","unstructured":"Motosugi U, Ichikawa T, Sou H et al (2010) Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology 256:151\u2013158. https:\/\/doi.org\/10.1148\/radiol.10091885","journal-title":"Radiology"},{"key":"2402_CR131","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-022-05956-w","volume":"50","author":"R Salem","year":"2023","unstructured":"Salem R, Padia SA, Lam M et al (2023) Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging 50:328\u2013343. https:\/\/doi.org\/10.1007\/s00259-022-05956-w","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2402_CR132","doi-asserted-by":"publisher","unstructured":"Tsurusaki M, Sofue K, Murakami T, Tanigawa N (2024) Radiological assessment and therapeutic evaluation in hepatocellular carcinoma: differentiation and treatment response with Japanese guidelines. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17010101","DOI":"10.3390\/cancers17010101"},{"key":"2402_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.medntd.2024.100327","volume":"24","author":"HT Vengateswaran","year":"2024","unstructured":"Vengateswaran HT, Habeeb M, You HW, Aher KB, Bhavar GB, Asane GS (2024) Hepatocellular carcinoma imaging: exploring traditional techniques and emerging innovations for early intervention. Med Novel Technol Devices 24:100327. https:\/\/doi.org\/10.1016\/j.medntd.2024.100327","journal-title":"Med Novel Technol Devices"},{"key":"2402_CR134","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/hepr.13746","volume":"52","author":"M Kudo","year":"2022","unstructured":"Kudo M, Ikeda M, Ueshima K et al (2022) Response evaluation criteria in cancer of the liver version 6 (response evaluation criteria in cancer of the liver 2021 revised version). Hepatol Res 52:329\u2013336. https:\/\/doi.org\/10.1111\/hepr.13746","journal-title":"Hepatol Res"},{"key":"2402_CR135","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.764189","volume":"11","author":"M Zhou","year":"2021","unstructured":"Zhou M, Zhang C, Nie J et al (2021) Response evaluation and survival prediction following PD-1 inhibitor in patients with advanced hepatocellular carcinoma: comparison of the RECIST 1.1, iRECIST, and mRECIST criteria. Front Oncol 11:764189. https:\/\/doi.org\/10.3389\/fonc.2021.764189","journal-title":"Front Oncol"},{"key":"2402_CR136","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1148\/radiol.2019182867","volume":"292","author":"SM Lee","year":"2019","unstructured":"Lee SM, Lee JM, Ahn SJ, Kang HJ, Yang HK, Yoon JH (2019) LI-RADS version 2017 versus version 2018: diagnosis of hepatocellular carcinoma on gadoxetate disodium-enhanced MRI. Radiology 292:655\u2013663. https:\/\/doi.org\/10.1148\/radiol.2019182867","journal-title":"Radiology"},{"key":"2402_CR137","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-019-0266-9","volume":"19","author":"H Jiang","year":"2019","unstructured":"Jiang H, Liu X, Chen J et al (2019) Man or machine? Prospective comparison of the version 2018 EASL, LI-RADS criteria and a radiomics model to diagnose hepatocellular carcinoma. Cancer Imaging 19:84. https:\/\/doi.org\/10.1186\/s40644-019-0266-9","journal-title":"Cancer Imaging"},{"key":"2402_CR138","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1007\/s00261-019-02077-1","volume":"44","author":"SH Hwang","year":"2019","unstructured":"Hwang SH, Park S, Han K, Choi JY, Park YN, Park MS (2019) Optimal lexicon of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of hepatocellular carcinoma modified from LI-RADS. Abdom Radiol (NY) 44:3078\u20133088. https:\/\/doi.org\/10.1007\/s00261-019-02077-1","journal-title":"Abdom Radiol (NY)"},{"key":"2402_CR139","doi-asserted-by":"publisher","first-page":"7786","DOI":"10.26355\/eurrev_201909_18988","volume":"23","author":"AM De Gaetano","year":"2019","unstructured":"De Gaetano AM, Catalano M, Pompili M et al (2019) Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (\u2264 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging. Eur Rev Med Pharmacol Sci 23:7786\u20137801. https:\/\/doi.org\/10.26355\/eurrev_201909_18988","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2402_CR140","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3350\/cmh.2020.0004","volume":"26","author":"S Lee","year":"2020","unstructured":"Lee S, Kim SS, Chang DR, Kim H, Kim MJ (2020) Comparison of LI-RADS 2018 and KLCA\u2013NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging. Clin Mol Hepatol 26:340\u2013351. https:\/\/doi.org\/10.3350\/cmh.2020.0004","journal-title":"Clin Mol Hepatol"},{"key":"2402_CR141","doi-asserted-by":"publisher","first-page":"319.e1","DOI":"10.1016\/j.crad.2019.11.004","volume":"75","author":"A Ko","year":"2020","unstructured":"Ko A, Park HJ, Lee ES et al (2020) Comparison of the diagnostic performance of the 2017 and 2018 versions of LI-RADS for hepatocellular carcinoma on gadoxetic acid enhanced MRI. Clin Radiol 75:319.e1\u2013319.e9. https:\/\/doi.org\/10.1016\/j.crad.2019.11.004","journal-title":"Clin Radiol"},{"key":"2402_CR142","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1007\/s00330-019-06546-5","volume":"30","author":"SH Park","year":"2020","unstructured":"Park SH, Kim B, Kim SY et al (2020) Abbreviated MRI with optional multiphasic CT as an alternative to full-sequence MRI: LI-RADS validation in a HCC-screening cohort. Eur Radiol 30:2302\u20132311. https:\/\/doi.org\/10.1007\/s00330-019-06546-5","journal-title":"Eur Radiol"},{"key":"2402_CR143","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/jmri.28056","volume":"56","author":"H Jiang","year":"2022","unstructured":"Jiang H, Song B, Qin Y et al (2022) Modifying LI-RADS on gadoxetate disodium-enhanced MRI: a secondary analysis of a prospective observational study. J Magn Reson Imaging 56:399\u2013412. https:\/\/doi.org\/10.1002\/jmri.28056","journal-title":"J Magn Reson Imaging"},{"key":"2402_CR144","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.3348\/kjr.2020.0846","volume":"22","author":"SM Lee","year":"2021","unstructured":"Lee SM, Lee JM, Ahn SJ, Kang HJ, Yang HK, Yoon JH (2021) Diagnostic performance of 2018 KLCA\u2013NCC practice guideline for hepatocellular carcinoma on gadoxetic acid-enhanced MRI in patients with chronic hepatitis B or cirrhosis: comparison with LI-RADS version 2018. Korean J Radiol 22:1066\u20131076. https:\/\/doi.org\/10.3348\/kjr.2020.0846","journal-title":"Korean J Radiol"},{"key":"2402_CR145","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.crad.2020.12.007","volume":"76","author":"CGD Clarke","year":"2021","unstructured":"Clarke CGD, Albazaz R, Smith CR et al (2021) Comparison of LI-RADS with other non-invasive liver MRI criteria and radiological opinion for diagnosing hepatocellular carcinoma in cirrhotic livers using gadoxetic acid with histopathological explant correlation. Clin Radiol 76:333\u2013341. https:\/\/doi.org\/10.1016\/j.crad.2020.12.007","journal-title":"Clin Radiol"},{"key":"2402_CR146","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.acra.2020.04.003","volume":"28","author":"HF Liu","year":"2021","unstructured":"Liu HF, Xu YS, Liu Z et al (2021) Value of Gd-EOB-DTPA-enhanced MRI and diffusion-weighted imaging in detecting residual hepatocellular carcinoma after drug-eluting bead transarterial chemoembolization. Acad Radiol 28:790\u2013798. https:\/\/doi.org\/10.1016\/j.acra.2020.04.003","journal-title":"Acad Radiol"}],"container-title":["Insights into Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-026-02402-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13244-026-02402-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-026-02402-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:03:24Z","timestamp":1790615004000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13244-026-02402-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":146,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2402"],"URL":"https:\/\/doi.org\/10.1186\/s13244-026-02402-5","relation":{},"ISSN":["1869-4101"],"issn-type":[{"value":"1869-4101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"19 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"237"}}